CANCER DIAGNOSTICS MARKET The global cancer burden encompassed 53.5 million people living with cancer1, 20.0 million new cases and 9.7 million deaths in 2022.2 The incidence of cancer is expected to reach 35 million new cases by 2050 due to population aging and growth. Cancer is a leading cause of premature death with the highest burdens in China, Europe and North America. The cancer burden can be reduced by improved prevention, early detection, cancer screening programs and effective treatment to improve patient outcomes and reduce mortality. Cancer is often detected at late-stage (Stages III and IV) after symptoms have appeared, resulting in a poor prognosis. Many existing diagnostic tests have high false-positives and/or lack sensitivity for early-stage cancer (Stages I and II) and screening programs have poor participation rates due to the test invasiveness, inconvenience, inaccessibility and cost. Earlier, more accurate and cost-effective diagnostics could improve treatment options, patient outcomes and survival.3 INOVIQ is developing non-invasive diagnostics using its proprietary exosome (liquid biopsies and companion diagnostics) and SubB2M (improves existing cancer biomarker tests) technologies for screening, diagnosis, treatment selection and monitoring of cancer and other diseases. INOVIQ’s diagnostics pipeline currently includes blood tests for detection and monitoring of ovarian and breast cancers. Ovarian cancer is the world’s deadliest gynaecological cancer with 314,000 cases and 207,000 deaths worldwide2, and a global diagnostic market expected to reach US$5.5 billion by 2030.4 Breast cancer is the most common cancer with 2.3 million cases and 685 million deaths worldwide2, and a global diagnostics market expected to reach US$8.5 billion by 2030.5 EXOSOMES MARKET FOR RESEARCH, DIAGNOSTIC AND THERAPEUTIC APPLICATIONS Exosomes (or small extracellular vesicles, EVs) are released by all cells and perform key roles in intercellular communication, immune regulation and disease progression. They carry molecular cargo including DNA, RNAs, proteins and lipids that act as cell messengers or biomarkers of disease. Exosomes have enormous potential in applications for research, diagnosis and treatment of cancer, neurodegenerative, cardiovascular, infectious and other diseases. The global exosome research market was valued at US$177.4m in 2024 and is forecast to reach US$794.2m by 2030, growing at a CAGR of 28.7%.6 Another report valued the global exosome market for diagnostics and therapeutics at US$59 million in 2024 and is forecast to reach US$6.8 billion by 2032, growing at a CAGR of 81.2% as more diagnostics and therapeutics are commercialised.7 Market growth is driven by increased investment in exosome research, the rising prevalence of chronic diseases, and adoption of liquid biopsies and precision medicine. The key challenge remains inadequate exosome isolation and production methods. INOVIQ is harnessing the power of exosomes for biomarker discovery, diagnostic and therapeutic applications. The Company has commercialised its EXONET exosome isolation technology with global distribution partner Promega, is advancing diagnostic tests for screening ovarian cancer, and progressing preclinicalstage exosome therapeutics for solid tumours. 1 The Global Cancer Observatory, GLOBOCAN 2022 World Fact Sheet 2 Bray, F et al. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021. doi: 10.3322/caac.21834 3 SEER18 2010-2016 4 2024. Ovarian Cancer Diagnostics Market, 2024-2030. https://www.grandviewresearch.com/industry-analysis/ ovarian-cancer-diagnostics-market 5 2025. Breast Cancer Diagnostics Market, 2025-2030: https://www.grandviewresearch.com/industry-analysis/ breast-cancer-diagnostics-market 6 2025. Exosomes Market Size, Share and Trends Analysis Report, 2025-2030. https://www.grandviewresearch.com/ industry-analysis/exosomes-market 7 2024. Exosome Diagnostics and Therapeutics Market to 2032. MarketsandMarkets: https://www.marketsandmarkets. com/Market-Reports/exosome-diagnostics-therapeuticsmarket-198025144.html Extracellular Vesicle (EV) 6 INOVIQ Limited Review of Operations continued
RkJQdWJsaXNoZXIy MjE2NDg3